595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study

ABSTRACT:

SUBMITTER: Han G 

PROVIDER: S-EPMC8644769 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature